Amyloidosis secondary to hidradenitis suppurativa. Exceptional response to infliximab.
Montes-Romero
J A
JA
Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital Universitario San Cecilio, Granada, Spain.
Callejas-Rubio
J L
JL
Sánchez-Cano
D
D
González-Martínez
F J
FJ
Navas-Parejo
A
A
Ortego-Centeno
N
N
D000328:Adult; D000686:Amyloidosis / Q000188:drug therapy / Q000209:etiology*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017497:Hidradenitis Suppurativa / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D000069285:Infliximab; D008297:Male; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab